07 June 2024
07 June 2024
The regulatory decision is grounded in the positive results from the IMerge Phase III clinical trial.
Keeping high-qualified, experienced clinical trial staff on board plays a crucial role in bringing new drugs to market.
The acquisition follows a successful initial partnership between the two companies which began in July 2023.
An FDA advisory committee voted unanimously in favour of updating Covid-19 vaccines to target the JN.1 variant.
Anti-trust regulator AGCM alleges that the companies colluded to delay the Italian market launch of eye drug Byooviz.
Vanda's board will review Cycle's unsolicited proposal to determine the best course for the company and its shareholders.
Global investment company Temasek spearheaded the funding round.
Moderna is developing mRNA-3705 for methylmalonic acidemia (MMA), and Myrtelle is developing rAAV-Olig001 for Canavan disease (CD).
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
